Expression of Urotensin II and Its Receptor in Human Liver Cirrhosis and Fulminant Hepatic Failure
暂无分享,去创建一个
[1] H. Krum,et al. Increased circulating urotensin II in cirrhosis: Potential implications in liver disease , 2008, Peptides.
[2] H. Krum,et al. Urotensin II in chronic liver disease: In vivo effect on vascular tone , 2008, Scandinavian journal of gastroenterology.
[3] F. Lammert,et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats , 2007, Hepatology.
[4] H. Krum,et al. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[5] P. Pacaud,et al. Urotensin II is a New Chemotactic Factor for UT Receptor-Expressing Monocytes1 , 2007, The Journal of Immunology.
[6] Z. Ao,et al. Urotensin II and renal function in the rat. , 2006, Kidney international.
[7] A. Davenport,et al. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation , 2006, British journal of pharmacology.
[8] N. Ashton,et al. Urotensin II: Ancient Hormone with New Functions in Vertebrate Body Fluid Regulation , 2005, Annals of the New York Academy of Sciences.
[9] N. Aiyar,et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[10] Werner Müller,et al. Interleukin 6/gp130‐dependent pathways are protective during chronic liver diseases , 2003, Hepatology.
[11] T. Yoshimoto,et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. , 2003, Endocrinology.
[12] O. Nayler,et al. The Expression of Urotensin II Receptor (U2R) is Up‐regulated by Interferon‐γ , 2003, Journal of receptor and signal transduction research.
[13] T. Dschietzig,et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure , 2002, Regulatory Peptides.
[14] C. Trautwein,et al. Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B , 2002, Hepatology.
[15] T. Sauerbruch,et al. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. , 2001, Journal of hepatology.
[16] A. Davenport,et al. Depressor and regionally‐selective vasodilator effects of human and rat urotensin II in conscious rats , 2001, British journal of pharmacology.
[17] S. Douglas,et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. , 2001, American journal of physiology. Heart and circulatory physiology.
[18] H. Sarau,et al. Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey , 2000, British journal of pharmacology.
[19] N. Aiyar,et al. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. , 2000, Journal of cardiovascular pharmacology.
[20] Roger Williams,et al. The systemic inflammatory response syndrome in acute liver failure , 2000, Hepatology.
[21] S. Douglas,et al. Human urotensin‐II is an endothelium‐dependent vasodilator in rat small arteries , 2000, British journal of pharmacology.
[22] H. Sarau,et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.
[23] M. Manns,et al. Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. , 1999, The American journal of pathology.
[24] R. Persaud,et al. Statistics: the glitter of the t table , 1993, The Lancet.
[25] Roger Williams,et al. Acute liver failure: redefining the syndromes , 1993, The Lancet.